Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Walther, EU; Dang, T; Hartung, HP; Hohlfeld, R.
Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure
Nervenarzt. 1997; 68(12):935-939
Doi: 10.1007/s001150050219
Web of Science
PubMed
FullText
FullText_MUG
- Autor*innen der Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Interferon beta-1b has been shown to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). In the North American study, however, approximately 35% of patients developed neutralizing antibodies leading to a diminution of therapeutic efficacy according to current investigations. In contrast, antibody-negative patients showed a 50% reduction in the annual relapse rate compared to patients receiving placebo. Here we provide practical guidelines for neutralizing antibody testing if treatment failure is suspected.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - administration and dosage
- Antibody Formation - immunology
- Humans - immunology
- Interferon-beta - administration and dosage
- Multiple Sclerosis - diagnosis
- Neurologic Examination - drug effects
- Neutralization Tests - drug effects
- Treatment Failure - drug effects
- Find related publications in this database (Keywords)
- Interferon Beta
- Multiple Sclerosis
- Therapy
- Neutralizing Antibodies